No Data
No Data
Morgan Stanley has released the "China AI 60" list! In addition to Tencent and Alibaba, these companies are also on the list.
The competitiveness of AI in China has shifted from 'catching up in computing power' to 'defining applications.'
Market Chatter: WuXi AppTec Chairman Tops China's A-List for Highest Pay in 2024
Shenzhen Mindray Bio-Medical Electronics (300760): Performance meets expectations, and domestic performance is expected to迎来 a turning point in recovery by 2025.
Event description: The company released the 2024 annual report and the Q1 2025 report: In 2024, the company achieved revenue of 36.726 billion yuan, a year-on-year increase of 5.14%; the net income attributable to the parent company was 11.668 billion yuan, a year-on-year increase.
Research Reports Gold Digging | Huaan: Shenzhen Mindray Bio-Medical Electronics' overseas expansion is gradually improving, maintaining a "Buy" rating.
On May 7, according to Huaan's Research Reports, Shenzhen Mindray Bio-Medical Electronics (300760.SZ) is expected to achieve a net income of 11.668 billion yuan in 2024, a year-on-year increase of 0.74%; in the first quarter of 2025, a net income of 2.629 billion yuan, a year-on-year decrease of 16.81%. Domestic growth is under pressure, while overseas markets maintain high growth. With the easing of local financial pressures since 2025, the rebound in the issuance scale of medical special bonds, and the initiation of medical device upgrade projects led by the National Development and Reform Commission, the domestic market is expected to see a positive growth rate in the third quarter of this year, marking a rebound. With the ongoing deepening of localized platform construction, it is expected...
Shenzhen Mindray Bio-Medical Electronics (300760): The overseas market supports performance growth, and IVD has become the company's largest Business.
The company has released its annual report for 2024 and the first quarter report for 2025, with an annual revenue of 36.726 billion yuan in 2024, a year-on-year increase of 5.14%; the net income attributable to the parent company is 11.668 billion yuan, a year-on-year increase of 0.
Shenzhen Mindray Bio-Medical Electronics (300760): Short-term pressure under multiple policy disruptions, accelerating the implementation of the Global Strategy for high-end and internationalization.
Event: The company released its annual report for 2024 and the first quarter report for 2025, with a revenue of 36.726 billion yuan in 2024, a year-on-year increase of 5.14%, where domestic Business declined by 5.10%, and overseas income grew by 2.